Syncona Investee Nightstar Gets Positive News From US Regulator

LONDON (Alliance News) - Healthcare investor Syncona Ltd on Thursday said its portfolio firm ...

Alliance News 14 June, 2018 | 11:58AM
Email Form

LONDON (Alliance News) - Healthcare investor Syncona Ltd on Thursday said its portfolio firm Nightstar Therapeutics PLC has been granted a regenerative medicine advanced therapy designation from the US Food & Drug Administration.

Nightstar's NSR-REP1 treatment is currently in phase III development for the treatment of choroideremia, which is a degenerative retinal disorder leading to blindness.

Syncona shares were up 0.2% Thursday at 225.39 pence apiece.

By George Collard; georgecollard@alliancenews.com

Copyright 2018 Alliance News Limited. All Rights Reserved.

Email Form
Securities Mentioned in Article
Security Name Price Change (%) Morningstar
Rating
Syncona Ord 264.50 GBX 0.38 -
About Author Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.